Listen: Pharma’s bitter dose of tariff pressure
President Trump has imposed a 15% tariff on EU pharmaceuticals and threatened even steeper levies elsewhere. At the same time, however, he is demanding that drug companies at home lower their prices. In this podcast, ING's Diederik Stadig explains why these competing aims cannot be reconciled, and what it could all mean for the industry and for consumers
Following months of high-stakes negotiations, a US-EU trade deal has now been clinched, with a 15% tariff on most EU exports replacing the feared 30% threatened by Trump earlier this year. The White House has since confirmed that pharmaceuticals will fall under this 15% threshold.
While the decision offers some clarity to EU companies, uncertainty looms elsewhere. Switzerland faces a steep 39% tariff on exports, though pharmaceuticals appear exempt for now. Meanwhile, India - a major supplier of generic drugs - could be hit with a 25% tariff.
In this podcast, ING's Diederik Stadig joins Rebecca Byrne and Olivia Grace to discuss the implications for the pharma industry, for consumers, and for Trump's strategy itself.
Questa pubblicazione è stata preparata da ING esclusivamente a scopo informativo, indipendentemente dai mezzi, dalla situazione finanziaria o dagli obiettivi di investimento di un particolare utente. Le informazioni non costituiscono una raccomandazione di investimento e non sono consigli di investimento, legali o fiscali né un'offerta o una sollecitazione all'acquisto o alla vendita di alcun strumento finanziario. Leggi di più